Esophageal Cancer. -Thoracic part of oesophagus-Abdominal part of oesophagus-Cardia
Conditions
Interventions
Intervention 1: Patients treat with the combination of cisplatin 30 mg per square meter and irinotecan 65 mg per square meter in days1 and 8 every 3 weeks at least 2 cycles during a course of 5-6 wee
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciencesice
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Primary esophageal cancer(adenocarcinoma or squamous cell carcinoma) No distant metastasis Maximum age 75 years Performance Status>70% Stable hematologic status Normal liver and kidney function Patient consent suitable for surgery Exclusion Criteria: Metastatic disease Cervical Esophageal Cancer Thracheoesophageal fistula Previous or current another malignant disease Any major surgery within the past 4 weeks.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival Rate. Timepoint: 1- Every 3 months after start of intervention. 2- Following every cycle of chemotherapy. Method of measurement: Months that patient is without any sign or recurrent disease and survive after start of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1- Disease Free Survival (DFS) 2- Treatment toxicity. Timepoint: Every 3 months after start of intervention also following every cycle of chemotherapy. Method of measurement: Months that patient survive after start of intervention. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMitra Fazl Ersi
Cancer Reasearch Center
Outcome results
None listed